FY2025 Earnings Estimate for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Equities research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of OmniAb in a report released on Wednesday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.50) per share for the year, up from their previous forecast of ($0.59). The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s Q4 2025 earnings at ($0.06) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at ($0.16) EPS.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank Of Canada dropped their price objective on OmniAb from $4.00 to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Weiss Ratings restated a “sell (e+)” rating on shares of OmniAb in a report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, OmniAb presently has an average rating of “Moderate Buy” and a consensus price target of $6.67.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $1.38 on Friday. The stock has a 50 day moving average price of $1.61 and a 200 day moving average price of $1.70. The stock has a market capitalization of $198.66 million, a PE ratio of -2.38 and a beta of 0.15. OmniAb has a 52 week low of $1.22 and a 52 week high of $4.71.

OmniAb (NASDAQ:OABI) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. OmniAb had a negative return on equity of 23.14% and a negative net margin of 301.83%.The company had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $5.64 million. OmniAb has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On OmniAb

Large investors have recently modified their holdings of the stock. Osaic Holdings Inc. boosted its holdings in shares of OmniAb by 214.4% during the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after buying an additional 9,716 shares during the period. AQR Capital Management LLC bought a new position in OmniAb in the 1st quarter valued at about $25,000. Cerity Partners LLC acquired a new stake in OmniAb during the first quarter worth approximately $26,000. PNC Financial Services Group Inc. lifted its position in OmniAb by 279.4% during the first quarter. PNC Financial Services Group Inc. now owns 16,276 shares of the company’s stock worth $39,000 after acquiring an additional 11,986 shares during the last quarter. Finally, Corient Private Wealth LLC bought a new stake in shares of OmniAb during the second quarter worth approximately $53,000. 72.08% of the stock is owned by institutional investors.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.